EA030253B1 - Азахиназолиновые ингибиторы атипичной протеинкиназы c - Google Patents

Азахиназолиновые ингибиторы атипичной протеинкиназы c Download PDF

Info

Publication number
EA030253B1
EA030253B1 EA201590661A EA201590661A EA030253B1 EA 030253 B1 EA030253 B1 EA 030253B1 EA 201590661 A EA201590661 A EA 201590661A EA 201590661 A EA201590661 A EA 201590661A EA 030253 B1 EA030253 B1 EA 030253B1
Authority
EA
Eurasian Patent Office
Prior art keywords
optionally substituted
pyridin
cyclopropyl
pyrido
pyrimidin
Prior art date
Application number
EA201590661A
Other languages
English (en)
Russian (ru)
Other versions
EA201590661A1 (ru
Inventor
Генри Дж. Бреслин
Брюс Д. Дорси
Бенджамин Дж. Дуган
Кэтрин М. Фаулер
Роберт Л. Хадкинз
Юджин Ф. Месарос
Натаниэль ДжТ Монк
Эмма Л. Моррис
Икеолува Оловойе
Грегори Р. Отт
Грегуар А. Пейв
Джонатан Р.А. Роффи
Кристелль Н. Соуди
Мин Тао
Крейг А. Зификсак
Эллисон Л. Зулли
Original Assignee
Кэнсэр Ресерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсэр Ресерч Текнолоджи Лимитед filed Critical Кэнсэр Ресерч Текнолоджи Лимитед
Publication of EA201590661A1 publication Critical patent/EA201590661A1/ru
Publication of EA030253B1 publication Critical patent/EA030253B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201590661A 2012-09-28 2013-09-27 Азахиназолиновые ингибиторы атипичной протеинкиназы c EA030253B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261707340P 2012-09-28 2012-09-28
US201361781364P 2013-03-14 2013-03-14
PCT/US2013/062085 WO2014052699A1 (en) 2012-09-28 2013-09-27 Azaquinazoline inhibitors of atypical protein kinase c

Publications (2)

Publication Number Publication Date
EA201590661A1 EA201590661A1 (ru) 2015-09-30
EA030253B1 true EA030253B1 (ru) 2018-07-31

Family

ID=49326872

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590661A EA030253B1 (ru) 2012-09-28 2013-09-27 Азахиназолиновые ингибиторы атипичной протеинкиназы c

Country Status (18)

Country Link
US (2) US9914730B2 (OSRAM)
EP (1) EP2900666B1 (OSRAM)
JP (1) JP6535430B2 (OSRAM)
KR (1) KR102215272B1 (OSRAM)
CN (1) CN105102456B (OSRAM)
AU (1) AU2013323360B2 (OSRAM)
BR (1) BR112015007061B1 (OSRAM)
CA (1) CA2886495C (OSRAM)
CL (1) CL2015000781A1 (OSRAM)
EA (1) EA030253B1 (OSRAM)
IL (1) IL237918B (OSRAM)
MX (1) MX372736B (OSRAM)
NZ (1) NZ706857A (OSRAM)
PH (1) PH12015500689B1 (OSRAM)
SG (1) SG11201502301YA (OSRAM)
TW (1) TWI663165B (OSRAM)
WO (1) WO2014052699A1 (OSRAM)
ZA (1) ZA201502783B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013323360B2 (en) * 2012-09-28 2017-09-07 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase C
JP6391120B2 (ja) 2012-12-20 2018-09-19 サンフォード−バーンハム メディカル リサーチ インスティテュート ニューロテンシン受容体1の小分子アゴニスト
KR102295740B1 (ko) 2013-03-14 2021-09-01 베링거 인겔하임 인터내셔날 게엠베하 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드
US9550770B2 (en) 2013-08-23 2017-01-24 Neupharma, Inc. Substituted quinazolines for inhibiting kinase activity
WO2015143376A1 (en) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Novel compounds for the treatment of cystic fibrosis
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
CA2952732C (en) 2014-06-25 2024-01-02 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
WO2016004272A1 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2960101C (en) * 2014-09-05 2024-05-21 Allosteros Therapeutics, Inc. Substituted carboline derivative and compositions thereof useful as camkii inhibitors
BR112017003433B1 (pt) 2014-09-12 2023-11-14 Boehringer Ingelheim International Gmbh Inibidores espirocíclicos de catepsina c, composição farmacêutica e uso dos mesmos
CA2962917C (en) * 2014-10-29 2019-04-30 Dong-A St Co., Ltd. Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CN105288512A (zh) * 2015-12-08 2016-02-03 李野林 一种治疗肥胖症的中药组合物
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
EP3497087B1 (en) 2016-08-15 2021-11-10 Neupharma, Inc. Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer
WO2018035080A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
JOP20190257A1 (ar) 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN111217797B (zh) 2017-06-30 2021-02-05 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US12492199B2 (en) * 2018-07-25 2025-12-09 Faes Farma, S.A. Pyridopyrimidines as histamine H4-receptor inhibitors
WO2020025030A1 (zh) * 2018-08-01 2020-02-06 上海轶诺药业有限公司 一类具有免疫调节功能的芳香化合物的制备和应用
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法
AU2020248096B2 (en) * 2019-03-28 2025-11-20 Cancer Research Technology Ltd Inhibitors of atypical protein kinase C and their use in treating hedgehog pathway-dependent cancers
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN116120243B (zh) * 2021-11-15 2025-07-29 都创(上海)医药科技股份有限公司 aPKC抑制剂化合物中间体片段及其制备方法和应用
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法
CN117088898A (zh) * 2022-05-13 2023-11-21 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
AU2023398000A1 (en) * 2022-12-13 2025-07-24 Windtree Therapeutics, Inc. Solid forms of {5-cyclopropyl-2-[2-(3,6-difluoro- pyridin-2-ylamino)-pyridin-4-yl]-pyrido[3,4-d]pyrimidin-4-yl}-((s)-3,3-dimethyl-piperidin-4-yl)-amine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936700A (OSRAM) 1972-08-16 1974-04-05
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002080423A (ja) * 2000-09-06 2002-03-19 Daikin Ind Ltd トリフルオロ酢酸エチルの合成方法
WO2002022605A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス, インク. Tie−2モジュレータと使用方法
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008531538A (ja) * 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド 2,4−ジアミノ−ピリドピリミジン誘導体とmTOR阻害剤としてのその使用
LT2057156T (lt) * 2006-08-23 2017-05-25 Kudos Pharmaceuticals Limited 2-metilmorfolino pirido-, pirazo- ir pirimidopirimidino dariniai kaip mtor slopikliai
EP2069344A2 (en) * 2006-09-08 2009-06-17 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2011029054A1 (en) * 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AU2013323360B2 (en) * 2012-09-28 2017-09-07 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase C
CA2904612A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016040330A1 (en) * 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
RU2018126774A (ru) * 2015-12-22 2020-01-23 Витэ Фармасьютикалз, Инк. Ингибиторы менин-mll взаимодействия

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONZALEZ CAMPOS R M, CROVETTO MONTOYA G, CROVETTO MONTOYA L, THOMAS GOMEZ J: "Estudio Oscilopolarografico de dos Derivados 5, 4d Pirimidinicos", ARS PHARMACEUTICA., GRANADA., ES, vol. 27, no. 3, 1 January 1986 (1986-01-01), ES, pages 255 - 261, XP009174013, ISSN: 0004-2927 *
MAURICE J. VAN EIS; JEAN-PIERRE EVENOU; PHILIPP FLOERSHEIM; CHRISTOPH GAUL; SANDRA W. COWAN-JACOB; LAUREN MONOVICH; GABRIELE RUMME: "2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 21, no. 24, 7 October 2011 (2011-10-07), AMSTERDAM, NL, pages 7367 - 7372, XP028113889, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2011.10.025 *
NISHIKAWA: "STRUCTURE-ACTIVITY RELATIONS OF THE DIURETIC ACTIVITY OF TRIAZA- AND TETRAAZANAPHTALENE COMPOUNDS", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 24, no. 9, 1 January 1976 (1976-01-01), JP, pages 2057 - 2077, XP008073154, ISSN: 0009-2363 *

Also Published As

Publication number Publication date
AU2013323360A1 (en) 2015-04-30
PH12015500689A1 (en) 2015-05-25
US20160102094A1 (en) 2016-04-14
EA201590661A1 (ru) 2015-09-30
NZ706857A (en) 2018-05-25
CN105102456A (zh) 2015-11-25
US20140113882A1 (en) 2014-04-24
IL237918B (en) 2021-05-31
AU2013323360B2 (en) 2017-09-07
JP2015533822A (ja) 2015-11-26
PH12015500689B1 (en) 2015-05-25
CL2015000781A1 (es) 2016-04-01
CA2886495C (en) 2023-09-19
US9914730B2 (en) 2018-03-13
TW201427978A (zh) 2014-07-16
BR112015007061B1 (pt) 2022-10-04
HK1212336A1 (en) 2016-06-10
KR20150086248A (ko) 2015-07-27
KR102215272B1 (ko) 2021-02-15
BR112015007061A2 (pt) 2017-07-04
JP6535430B2 (ja) 2019-06-26
ZA201502783B (en) 2016-01-27
EP2900666A1 (en) 2015-08-05
CN105102456B (zh) 2017-11-14
US9896446B2 (en) 2018-02-20
IL237918A0 (en) 2015-05-31
BR112015007061A8 (pt) 2019-08-20
MX2015004016A (es) 2016-02-18
SG11201502301YA (en) 2015-04-29
MX372736B (es) 2020-06-19
HK1211928A1 (en) 2016-06-03
WO2014052699A1 (en) 2014-04-03
WO2014052699A9 (en) 2015-07-16
TWI663165B (zh) 2019-06-21
EP2900666B1 (en) 2020-11-04
CA2886495A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
EA030253B1 (ru) Азахиназолиновые ингибиторы атипичной протеинкиназы c
AU2015271837B2 (en) Tank-binding kinase inhibitor compounds
EP3728252A1 (en) 4-azaindole compounds
JP2019081786A (ja) Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
KR20150059647A (ko) 키나제 억제제로서 유용한 이미다조트리아진카르보니트릴
JP2023523863A (ja) 新規大環状lrrk2キナーゼインヒビター
KR20200121823A (ko) 약학적 6,5 헤테로비시클릭 고리 유도체
EP2686321A1 (en) Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
CN110036012A (zh) 吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐
AU2022265323C1 (en) Heterocyclic compounds capable of activating sting
WO2023001794A1 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
CN119546604A (zh) 作为hpk1抑制剂的吡啶并[3,2-d]嘧啶
HK1211928B (en) Azaquinazoline inhibitors of atypical protein kinase c
HK1212336B (en) Azaquinazoline inhibitors of atypical protein kinase c

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ TM